EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.

EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.